Tianjin, 300074, China
NCT Number: NCT00471770
Pneumoniae Epidemiology Study in China
To determine the proportion of hospitalized pneumonia cases in children aged 60 months or less associated with vaccine-preventable Streptococcus pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, 23F).
Looking for future studies?
Notify MeKey information
Conditions
Age range
Up to 60 month
Sex eligibility
All sexes
Study type
Observational
Primary location
About this study
Subjects meeting the eligibility criteria, including parental informed consent to collect clinical-epidemiological information, will have a deep respiratory aspirate specimen to determine the etiology of the lower respiratory tract infection. Clinicians may obtain other diagnostic specimens, such as pleural fluid, lung tap, cerebrospinal fluid, nasopharyngeal culture, or serum for serological assays, as indicated clinically. The chest radiograph will be taken and read locally according to predetermined criteria and by staff radiologists trained in radiographic criteria for pneumonia. Bacterial isolates other than Streptococcus pneumoniae will be identified according to standardized procedures. S. pneumoniae isolates will be transported to central laboratories for confirmation of identity, serotyping and antibiotic resistance testing, using standard techniques. Serotype will be determined using type-specific sera (Quellung reaction). Antibiotic susceptibility to penicillin, cefuroxime, ceftriaxone, erythromycin, Amoxycillin, Ofloxacin, Vancomycin, and imipenem be conducted using E-test according to standardized procedures at the central facilities.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Age, 60 months or less
- Meets study criteria for clinical pneumonia
- All the examination are/can be done within (before or after) 72 hours to enrollment time
- Informed consent obtained from parent or guardian
Exclusion criteria
- Received any pneumococcal vaccine in the past
- Current or underlying conditions that would pose a hazard in obtaining the deep respiratory aspirate (e.g., bleeding diathesis, severe respiratory compromise and others as determined by clinician) Aspirates may be obtained from patients who are intubated
- Any other medical condition that in the opinion of the clinician/investigator would pose a hazard to the child by participating in the study
- Children with recurrent pneumonia will enter into the study on only one occasion
Treatment and study plan
Primary outcomes
-
The proportion of hospitalized pneumonia cases associated with vaccine-preventable S. Pneumoniae serotypes (4, 6B, 9V, 14, 18C, 19F, 23F).
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Registry information
Official study title
Epidemiological Study of Hospitalized Pediatric Pneumonia in China
Important dates
- Study start
- 2007
- Primary completion
- 2008
- Study completion
- 2008
- First posted
- May 10, 2007
- Registry last updated
- Mar 13, 2008
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124
Bacterial Infections, Bacterial Infections and Mycoses
Doral, Florida, United States
View Trial DetailsA Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538
Bacterial Infections, Bacterial Infections and Mycoses
Washington D.C., District of Columbia, United States
View Trial DetailsSafety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)
NCT05569954
Bacterial Infections, Bacterial Infections and Mycoses
Rosario, Santa Fe Province, Argentina
View Trial DetailsA Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults
NCT07019909
Bacterial Infections, Bacterial Infections and Mycoses
Hangzhou, Zhejiang, China
View Trial Details